He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what other programs and targets he calls out.

After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress

BiotechTV - News

[SPEAKER_00] Alright BiotechTV, it's Monday October 5th, we are in Boston, the world capital of biotech and now I'm interviewing someone who I followed from afar and I've always wanted to interview in person because I think this company just like oozes creativity. In fact, if you check out the homepage of their website, to me it's just like no other website I've seen for a biotech company. It's very cool. So the company is Insilico Medicine and this is the chairman and CEO out of the company.

[SPEAKER_00] Alex Zhavoronkov, it's great to see you.

[SPEAKER_02] Very happy to be with you today.

[SPEAKER_00] Yep. So the reason we're doing this is you're part of a big meeting that just happened over the last handful of days here in Boston. It's the ARDD, Aging Research Drug Discovery Conference. You know, longevity is a word that like I always say with everything there's like the full spectrum of legitimacy. There's people that's doing it right and there's like hype.

[SPEAKER_00] And we're learning a lot as we go along. Tell us like what learnings from ARDD were for you this week.

[SPEAKER_02] Sure. Well, not only this week. So I'm in longevity space for 22 years now. It's actually a very long time. ARDD was founded, so I founded it, originally in Basel in Switzerland where Roche and Novartis are headquartered. And over the past 13 years we've seen many biotechs come into this world, present at ARDD and then die. And sometimes they actually did both of those kind of events happened during ARDD.

After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress

Read the full transcript

The candid version is on a podcast,
not the earnings call.

After a busy time in Boston during the Aging Research and Drug Discovery Meeting, Insilico Medicine CEO Alex Zhavoronkov discusses the latest in longevity therapeutics and Insilico's pipeline progress

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.